ArticleChest2021
Elastase Activity From Pseudomonas aeruginosa Respiratory Isolates and ICU Mortality.
Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Multiparameter Optimization ofJournal of medicinal chemistry · 2026Article
- Phenotypic and Whole-Genome Sequencing-Based Profiling of Antimicrobial Resistance and Virulence inGenes · 2026Article
- Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives.ChemMedChem · 2026Review
- Genetic Analysis of Virulence and β-Lactamase Determinants Related to β-Lactamase Inhibitors inAntibiotics (Basel, Switzerland) · 2025Article
- Unraveling the immunosuppressive role of Elastase B produced by cystic fibrosis isolates ofVirulence · 2025Article
- Evolutionary loss of an antibiotic efflux pump increases Pseudomonas aeruginosa quorum sensing mediated virulence in vivo.Nature communications · 2025Article
- Risk factors for multidrug resistant and carbapenem resistant Pseudomonas aeruginosa bloodstream infections among inpatients in Central and East China.Scientific reports · 2025Article
- Genomic virulence markers are associated with severe outcomes in patients with Pseudomonas aeruginosa bloodstream infection.Communications medicine · 2024Article
- Quercetin: a promising virulence inhibitor of Pseudomonas aeruginosa LasB in vitro.Applied microbiology and biotechnology · 2024Article
- In Vivo Evolution of a Klebsiella pneumoniae Capsule Defect With wcaJ Mutation Promotes Complement-Mediated Opsonophagocytosis During Recurrent Infection.The Journal of infectious diseases · 2024Article
- Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University.Scientific reports · 2024Article
- Effect ofFrontiers in microbiology · 2024Article
- Inhibitors of the Elastase LasB for the Treatment ofACS central science · 2023Article
- Higher levels of Pseudomonas aeruginosa LasB elastase expression are associated with early-stage infection in cystic fibrosis patients.Scientific reports · 2023Article
- An integrated multi-omics analysis of identifies distinct molecular characteristics in pulmonary infections of Pseudomonas aeruginosa.PLoS pathogens · 2023Article
- Chemical Optimization of SelectiveACS infectious diseases · 2023Article
- A survey of elastase-producing bacteria and characteristics of the most potent producer, Priestia megaterium gasm32.PloS one · 2023Article
- Resistance Is Not Futile: The Role of Quorum Sensing Plasticity inMicroorganisms · 2022Review
- Clinical Strains ofJournal of inflammation research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPseudomonas aeruginosa (PA) is a common cause of respiratory infection and morbidity. Pseudomonas elastase is an important virulence factor regulated by the lasR gene. Whether PA elastase activity is associated with worse clinical outcomes in ICU patients is unknown. RESEARCH QUESTION: Is there an association between PA elastase activity and worse host outcomes in a cohort of ICU patients?
methodsPA respiratory isolates from 238 unique ICU patients from two tertiary-care centers within the University of Pittsburgh Medical Center health system were prospectively collected and screened for total protease and elastase activity, biofilm production, antimicrobial resistance, and polymicrobial status. The association between pathogen characteristics and 30-day and 90-day mortality was calculated using logistic regression. For subgroup analysis, two patterns of early (≤72 h) and late sample (>72 h) collection from the index ICU admission were distinguished using a finite mixture model. Lung inflammation and injury was evaluated in a mouse model using a PA high elastase vs low elastase producer.
resultsPA elastase activity was common in ICU respiratory isolates representing 75% of samples and was associated with increased 30-day mortality (adjusted OR [95% CI]: 1.39 [1.05-1.83]). Subgroup analysis demonstrated that elastase activity was a risk factor for 30- and 90-day mortality in the early sample group, whereas antimicrobial resistance was a risk factor for 90-day mortality in the late sample group. Whole genome sequencing of high and low elastase producers showed that predicted loss-of-function lasR genotypes were less common among high elastase producers. Mice infected with a high elastase producer showed increased lung bacterial burden and inflammatory profile compared with mice infected with a low elastase producer.
interpretationElastase activity is associated with 30-day ICU mortality. A high elastase producing clinical isolate confers increased lung tissue inflammation compared with a low elastase producer in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.